Related Experiment Videos
Long-term pharmacologic management of atrial fibrillation in the elderly
1Department of Medicine, Division of Cardiology, Case Western Reserve University/University Hospitals of Cleveland, Cleveland, OH 44106, USA. alw2@po.cwru.edu
Insights
Treating elderly atrial fibrillation involves choosing between rate or rhythm control, both needing warfarin anticoagulation. Rhythm control requires careful antiarrhythmic drug selection based on structural heart disease presence and risk/benefit profiles.
Area of Science:
- Cardiology
- Geriatric Medicine
- Pharmacology
Background:
- Atrial fibrillation management in the elderly presents a critical therapeutic decision point.
- Both rate and rhythm control strategies necessitate anticoagulation therapy, typically with warfarin.
Purpose of the Study:
- To outline the decision-making process for selecting antiarrhythmic drug therapy in elderly patients with atrial fibrillation.
- To emphasize the crucial role of assessing structural heart disease in guiding antiarrhythmic drug choice.
Main Methods:
- Review of current treatment guidelines and clinical considerations for atrial fibrillation management.
- Analysis of antiarrhythmic drug efficacy and safety profiles in the context of structural heart disease.
Main Results:
- Warfarin anticoagulation is a cornerstone for both rate and rhythm control strategies.
- The presence or absence of structural heart disease significantly influences the selection of appropriate antiarrhythmic drugs.
- Risk/benefit assessment is paramount when considering antiarrhythmic use in patients with coronary artery disease, left ventricular dysfunction, or hypertension.
Conclusions:
- Antiarrhythmic drug selection for rhythm control in elderly atrial fibrillation patients must be individualized.
- A thorough evaluation of structural heart disease and patient comorbidities is essential for safe and effective treatment.
- Clinically reasoned approaches, prioritizing risk stratification, are vital for optimizing therapeutic outcomes.
Abstract:
The first decision to be made in treating atrial fibrillation in the elderly is to determine whether to pursue a treatment strategy of rate control or rhythm control. Both strategies require use of anticoagulation therapy with warfarin (target international normalized ratio, 2.5; range 2-3). If a decision is made for rhythm control, the critical therapy is almost always with an antiarrhythmic drug. Before selecting an antiarrhythmic drug for use, it is first necessary to determine the presence or absence of underlying structural heart disease, as that will affect the available options for antiarrhythmic drug use. If there is no underlying structural heart disease, any of the available antiarrhythmic drugs may be used, although a clinically reasoned approach is suggested. If there is underlying structural heart disease, not all antiarrhythmic drugs are appropriate for use. A clinically reasoned approach is suggested in the presence of coronary artery disease, left ventricular dysfunction /congestive heart failure, or hypertension based largely on the risk/benefit profile of the drugs.